Woolsey Pharmaceuticals Unveils Promising Results in ALS Treatment with BRAVYL® Reducing Toxic TDP-43 Spread
Woolsey Pharmaceuticals, a company at the forefront of neurodegenerative disease research, has recently unveiled significant findings regarding its investigational drug BRAVYL (oral fasudil) during the prestigious 35th International Symposium on ALS/MND in Montreal, Canada. The study, spearheaded by Dr. Daniel Linseman’s laboratory at the University of Denver, provided compelling evidence that BRAVYL treatment notably diminishes the spread of toxic TDP-43 pathology in patients suffering from Amyotrophic Lateral Sclerosis (ALS).
ALS is a devastating neurodegenerative disease characterized by the progressive degeneration of motor neurons, leading to severe physical incapacitation and ultimately, mortality. One of the prominent features of ALS is the abnormal accumulation and spread of TDP-43 protein aggregates, which can disrupt cellular functions and contribute to neuronal death. The current research focuses on understanding how TDP-43 pathology spreads through extracellular vesicles, notably via neuronal exosomes released by compromised neurons, which can then be absorbed by healthy neurons.
The findings from the recent study indicated that treatment with BRAVYL significantly reduced the aggregation of TDP-43, as well as its redistribution from the nucleus to the cytoplasm - a pathological process correlated with disease progression. Specifically, cells that were exposed to baseline exosomes derived from ALS patients displayed marked TDP-43 aggregation. However, after receiving BRAVYL for six months, the same patients' exosome samples led to a remarkable 60% and 61% reduction in TDP-43 aggregation and cytoplasmic relocation, respectively. These figures underscore the potential of BRAVYL to mitigate the harmful spread of TDP-43 pathology.
Sven Jacobson, CEO of Woolsey Pharmaceuticals, emphasized the implications of these findings: “We have previously shown that a six-month treatment of ALS patients with BRAVYL reduces Neurofilament Light Chain (NfL), and now we have evidence that BRAVYL can reduce the spread of toxic TDP-43, marking a groundbreaking discovery. These results highlight BRAVYL’s promise in transforming ALS treatment.”
Currently, work remains to identify the specific mechanisms and cargo involved in this process to further solidify BRAVYL’s position in ALS treatment strategies. Additionally, Woolsey Pharmaceuticals has completed recruitment for 31 ALS patients in a high-dose cohort for the REAL study, which is anticipated to yield further insights into the efficacy and safety of BRAVYL's higher dosing over time. Results from this study are expected to be unveiled in June 2025.
Given the bleak prognosis typically associated with ALS, where the mean survival can range from two to five years, any advancement that can inhibit the progression of TDP-43 pathology represents a vital step forward. Woolsey Pharmaceuticals stands committed to reshaping the landscape of ALS treatment, with a vision to improve and extend the lives of patients affected by this challenging condition.
As research into the mechanisms of neurodegenerative diseases continues, Woolsey Pharmaceuticals remains dedicated to uncovering new pathways and therapies that could offer hope to countless individuals facing ALS and other cognitive disorders. By bridging innovative research with clinical application, the company aims to transform the outlook for patients grappling with neurodegeneration.
ALS is a devastating neurodegenerative disease characterized by the progressive degeneration of motor neurons, leading to severe physical incapacitation and ultimately, mortality. One of the prominent features of ALS is the abnormal accumulation and spread of TDP-43 protein aggregates, which can disrupt cellular functions and contribute to neuronal death. The current research focuses on understanding how TDP-43 pathology spreads through extracellular vesicles, notably via neuronal exosomes released by compromised neurons, which can then be absorbed by healthy neurons.
The findings from the recent study indicated that treatment with BRAVYL significantly reduced the aggregation of TDP-43, as well as its redistribution from the nucleus to the cytoplasm - a pathological process correlated with disease progression. Specifically, cells that were exposed to baseline exosomes derived from ALS patients displayed marked TDP-43 aggregation. However, after receiving BRAVYL for six months, the same patients' exosome samples led to a remarkable 60% and 61% reduction in TDP-43 aggregation and cytoplasmic relocation, respectively. These figures underscore the potential of BRAVYL to mitigate the harmful spread of TDP-43 pathology.
Sven Jacobson, CEO of Woolsey Pharmaceuticals, emphasized the implications of these findings: “We have previously shown that a six-month treatment of ALS patients with BRAVYL reduces Neurofilament Light Chain (NfL), and now we have evidence that BRAVYL can reduce the spread of toxic TDP-43, marking a groundbreaking discovery. These results highlight BRAVYL’s promise in transforming ALS treatment.”
Currently, work remains to identify the specific mechanisms and cargo involved in this process to further solidify BRAVYL’s position in ALS treatment strategies. Additionally, Woolsey Pharmaceuticals has completed recruitment for 31 ALS patients in a high-dose cohort for the REAL study, which is anticipated to yield further insights into the efficacy and safety of BRAVYL's higher dosing over time. Results from this study are expected to be unveiled in June 2025.
Given the bleak prognosis typically associated with ALS, where the mean survival can range from two to five years, any advancement that can inhibit the progression of TDP-43 pathology represents a vital step forward. Woolsey Pharmaceuticals stands committed to reshaping the landscape of ALS treatment, with a vision to improve and extend the lives of patients affected by this challenging condition.
As research into the mechanisms of neurodegenerative diseases continues, Woolsey Pharmaceuticals remains dedicated to uncovering new pathways and therapies that could offer hope to countless individuals facing ALS and other cognitive disorders. By bridging innovative research with clinical application, the company aims to transform the outlook for patients grappling with neurodegeneration.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.